ArticleGeneral thoracic and cardiovascular surgery2026
Hypo-attenuated leaflet thickening after surgical aortic valve replacement with INSPIRIS RESILIA valve.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the incidence and early clinical impact of hypo-attenuated leaflet thickening (HALT) after surgical aortic valve replacement (SAVR) using the INSPIRIS RESILIA valve.
methodsBetween August 2020 and January 2025, 182 patients underwent SAVR with the INSPIRIS RESILIA valve, of whom 121 (66.5%) underwent cardiac computed tomography 1 week postoperatively. Anticoagulation consisted of heparin (target activated partial thromboplastin time, 1.5-2.0× control) followed by warfarin (target prothrombin time-international normalized ratio [PT-INR], 1.6-2.5). Parameters were compared between the HALT and non-HALT groups.
resultsHALT was detected in 22.3% (27/121) of patients. Among warfarin-treated patients (n = 94), mean PT-INR was 1.7 in the HALT group and 1.8 in the non-HALT group (p = 0.61). Patients with HALT were older (76.2 vs. 73.0 years, p = 0.10), and sex-adjusted odds ratio of HALT was 4.68 for patients aged ≥ 80 years as compared with those aged < 70 years (p = 0.03). Those with HALT had lower body surface area (1.46 vs. 1.58 m
conclusionsHALT occurred in approximately one-fifth of patients after SAVR with the INSPIRIS RESILIA valve. No signal of an increased risk of thromboembolic events associated with HALT was observed in this small cohort with a short-term follow-up.
Indexed as
Identifiers
42752753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.